|Articles|February 25, 2022
Defining the Course & Navigating the Finish Line
Author(s)Zipher Medical Affairs CO., LLC
Trending on PharmExec
1
Why High-Risk Patients Still Need Antivirals: Q&A with Gurinder S. Sidhu, M.D.
2
Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons
3
A Patent Strategy Pharma Execs May Be Overlooking: Means-Plus-Function Claims
4
Developing Better Drugs, Not Just More Drugs: Q&A with David Hung
5